Cargando…

Choosing the Right Partner for Medication Related Osteonecrosis of the Jaw: What Central European Dentists Know

Medication-related osteonecrosis of the jaw (MRONJ) is a side effect of antiresorptive drugs. In this online survey, the awareness and knowledge of dentists regarding MRONJ was evaluated, and potential implications for oncologists are discussed. Questionnaires were emailed to dentists from Germany,...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruckmoser, Emanuel, Palaoro, Miriam, Latzko, Lukas, Schnabl, Dagmar, Neururer, Sabrina B., Laimer, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122803/
https://www.ncbi.nlm.nih.gov/pubmed/33922326
http://dx.doi.org/10.3390/ijerph18094466
_version_ 1783692719702409216
author Bruckmoser, Emanuel
Palaoro, Miriam
Latzko, Lukas
Schnabl, Dagmar
Neururer, Sabrina B.
Laimer, Johannes
author_facet Bruckmoser, Emanuel
Palaoro, Miriam
Latzko, Lukas
Schnabl, Dagmar
Neururer, Sabrina B.
Laimer, Johannes
author_sort Bruckmoser, Emanuel
collection PubMed
description Medication-related osteonecrosis of the jaw (MRONJ) is a side effect of antiresorptive drugs. In this online survey, the awareness and knowledge of dentists regarding MRONJ was evaluated, and potential implications for oncologists are discussed. Questionnaires were emailed to dentists from Germany, Austria, Switzerland, and South Tyrol to evaluate disease-related knowledge and management. In addition to the overall score, a separate score was calculated for knowledge (maximum score: 15 points) and management (maximum score: 6 points) questions, and 1197 valid replies with completed questionnaires were received. The mean overall score was 10.45 ± 3.97 points, the mean knowledge score was 7.68 ± 3.05 points, and the mean management score was 2.76 ± 1.77 points. Factors influencing the outcome of the overall score were age, specialization, continuous professional education, and the number of dental screening exams in patients before antiresorptive therapy. Due to the considerable lack of knowledge regarding MRONJ among dentists, MRONJ patients and subjects at risk should be guided towards specialists for dental screening, treatment, and follow-up. This is important from an oncologic point of view to avoid any delay for treatment start of antiresorptives, and to reveal a potentially emerging osteonecrosis at an early stage, thus, avoiding the need for interruption or even cancellation of antiresorptive therapy.
format Online
Article
Text
id pubmed-8122803
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81228032021-05-16 Choosing the Right Partner for Medication Related Osteonecrosis of the Jaw: What Central European Dentists Know Bruckmoser, Emanuel Palaoro, Miriam Latzko, Lukas Schnabl, Dagmar Neururer, Sabrina B. Laimer, Johannes Int J Environ Res Public Health Article Medication-related osteonecrosis of the jaw (MRONJ) is a side effect of antiresorptive drugs. In this online survey, the awareness and knowledge of dentists regarding MRONJ was evaluated, and potential implications for oncologists are discussed. Questionnaires were emailed to dentists from Germany, Austria, Switzerland, and South Tyrol to evaluate disease-related knowledge and management. In addition to the overall score, a separate score was calculated for knowledge (maximum score: 15 points) and management (maximum score: 6 points) questions, and 1197 valid replies with completed questionnaires were received. The mean overall score was 10.45 ± 3.97 points, the mean knowledge score was 7.68 ± 3.05 points, and the mean management score was 2.76 ± 1.77 points. Factors influencing the outcome of the overall score were age, specialization, continuous professional education, and the number of dental screening exams in patients before antiresorptive therapy. Due to the considerable lack of knowledge regarding MRONJ among dentists, MRONJ patients and subjects at risk should be guided towards specialists for dental screening, treatment, and follow-up. This is important from an oncologic point of view to avoid any delay for treatment start of antiresorptives, and to reveal a potentially emerging osteonecrosis at an early stage, thus, avoiding the need for interruption or even cancellation of antiresorptive therapy. MDPI 2021-04-22 /pmc/articles/PMC8122803/ /pubmed/33922326 http://dx.doi.org/10.3390/ijerph18094466 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bruckmoser, Emanuel
Palaoro, Miriam
Latzko, Lukas
Schnabl, Dagmar
Neururer, Sabrina B.
Laimer, Johannes
Choosing the Right Partner for Medication Related Osteonecrosis of the Jaw: What Central European Dentists Know
title Choosing the Right Partner for Medication Related Osteonecrosis of the Jaw: What Central European Dentists Know
title_full Choosing the Right Partner for Medication Related Osteonecrosis of the Jaw: What Central European Dentists Know
title_fullStr Choosing the Right Partner for Medication Related Osteonecrosis of the Jaw: What Central European Dentists Know
title_full_unstemmed Choosing the Right Partner for Medication Related Osteonecrosis of the Jaw: What Central European Dentists Know
title_short Choosing the Right Partner for Medication Related Osteonecrosis of the Jaw: What Central European Dentists Know
title_sort choosing the right partner for medication related osteonecrosis of the jaw: what central european dentists know
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122803/
https://www.ncbi.nlm.nih.gov/pubmed/33922326
http://dx.doi.org/10.3390/ijerph18094466
work_keys_str_mv AT bruckmoseremanuel choosingtherightpartnerformedicationrelatedosteonecrosisofthejawwhatcentraleuropeandentistsknow
AT palaoromiriam choosingtherightpartnerformedicationrelatedosteonecrosisofthejawwhatcentraleuropeandentistsknow
AT latzkolukas choosingtherightpartnerformedicationrelatedosteonecrosisofthejawwhatcentraleuropeandentistsknow
AT schnabldagmar choosingtherightpartnerformedicationrelatedosteonecrosisofthejawwhatcentraleuropeandentistsknow
AT neururersabrinab choosingtherightpartnerformedicationrelatedosteonecrosisofthejawwhatcentraleuropeandentistsknow
AT laimerjohannes choosingtherightpartnerformedicationrelatedosteonecrosisofthejawwhatcentraleuropeandentistsknow